Newsroom

Recent News Releases

September 16, 2021 9/16/2021

Takeda Continues to Advance Growth Strategy with Sale Of Non-Core Assets in Latin America

September 15, 2021 9/15/2021

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

September 7, 2021 9/7/2021

Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

September 1, 2021 9/1/2021

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

August 6, 2021 8/6/2021

Takeda Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

SEE ALL NEWS AND RELEASES >

・For Shire news releases, click here

Featured Topics

Luck is not a strategy: The world needs to start preparing now for the next pandemic

Learn more

The COVID-19 Mental Burden on Working Mothers

Learn more

Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021

Learn more

Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts

Learn more

Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce

Learn more

SEE ALL FEATURED TOPICS ARTICLES >

In the News

With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.

LEARN MORE

Executive Leadership

Meet our Executive Leadership Team led by our President and CEO, Christophe Weber

LEARN MORE

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.